甘露聚糖肽联合舒巴坦治疗老年心力衰竭并肺部感染患者的临床疗效及其对心功能和免疫功能的影响研究

Clinical Effect of Mannatide Combined with Sulbactam in Treating Elderly Heart Failure Patients Complicated with Pulmonary Infection and the Impact on Cardiac Function and Immunologic Function

目的分析甘露聚糖肽联合舒巴坦治疗老年心力衰竭并肺部感染患者的临床疗效及其对心功能和免疫功能的影响。方法选取2014年3月—2016年3月衡水市第二人民医院收治的老年心力衰竭并肺部感染患者106例,随机分为对照组和观察组,每组53例。在常规治疗基础上,对照组患者予以舒巴坦治疗,观察组患者在对照组基础上加用甘露聚糖肽治疗;两组患者均连续治疗14 d。比较两组患者临床疗效及治疗前后心功能指标[左心房内径(LAD)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)及左心室射血分数(LVEF)]、外周血T淋巴细胞亚群(CD_3^+细胞分数、CD_4^+细胞分数、CD_8^+细胞分数及CD_4^+/CD_8^+细胞比值),并观察两组患者治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者LAD、LVEDD、LVESD、LVEF比较,差异无统计学意义(P>0.05);治疗后观察组患者LAD、LVEDD、LVESD小于对照组,LVEF高于对照组(P<0.05)。治疗前两组患者CD_3^+细胞分数、CD_4^+细胞分数、CD_8^+细胞分数、CD_4^+/CD_8^+细胞比值比较,差异无统计学意义(P>0.05);治疗后观察组患者CD_3^+细胞分数、CD_4^+细胞分数、CD_4^+/CD_8^+细胞比值高于对照组,CD_8^+细胞分数低于对照组(P<0.05)。两组患者治疗期间均未发生严重不良反应。结论甘露聚糖肽联合舒巴坦治疗老年心力衰竭并肺部感染患者的临床疗效确切,可有效改善患者心功能及免疫功能,且安全性较高。

Objective To analyze the clinical effect of mannatide combined with sulbactam in treating elderly heart failure patients complicated with pulmonary infection and the impact on cardiac function and immunologic function. Methods A total of 106 elderly heart failure patients complicated with pulmonary infection were selected in the Second People＇s Hospital of Hengshui from March 2014 to March 2016, and they were randomly divided into control group and observation group, each of 53 cases. Based on conventional treatment, patients of control group received sulbactam, while patients of observation group received mannatide combined with sulbactam; both groups continuously treated for 14 days. Clinical effect, index of cardiac function （including LAD, LVEDD, LVESD and LVEF） and peripheral blood T- lymphocyte subsets （including CD^3＋ cell percentage, CD4^＋ cell percentage, CD8^＋ cell percentage and CD4^＋/CD8^＋ cell ratio） before and after treatment were compared between the two groups, and incidence Of adverse reactions during the treatment was observed. Results Clinical effect of observation group was statistically significantly better than that of control group （P 〈 0. 05）. No statistically significant differences of LAD, LVEDD, LVESD or LVEF was found between the two groups before treatment （ P 〉 0. 05） ; after treatment, LAD, LVEDD and LVESD of observation group were statistically significantly less than those of control group, while LVEF of observation group was statistically significantly higher than that of control group （P 〈0. 05）. No statistically significant differences of CD3^＋ cell percentage, CD4^＋ cell percentage, CD8^＋ cell percentage or CD4^＋/CD8^＋ cell ratio was found between the two groups before treatment （ P 〉 0. 05 ） ; after treatment, CD; cell percentage, CD4^＋ cell percentage and CD4^＋/CD8^＋ cell ratio of observation group were statistically significantly higher than those of control group, while CD8^＋ cell percentage of observation group was statistically significantly lower than that of control group （P 〈 0. 05）. No one of the two groups occurred any serious adverse reactions during the treatment. Conclusion Mannatide combined with sulbactam has certain clinical effect in treating elderly heart failure patients complicated with pulmonary infection, can effectively improve the cardiac function and immunologic function, with relatively high safety.